开菲尔（Kefir）与肥胖
热点新闻
开菲尔（Kefir）是一种发酵乳饮料，已显示出减轻肥胖症和相关的代谢功能障碍的希望。但是，传统开菲尔中的微生物特性各不相同，而商用开菲尔与传统开菲尔有很大不同。这项研究调查了四种传统和一种商业牛乳气酒在高脂饮食诱导的肥胖小鼠模型中控制体重增加，血浆胆固醇和肝甘油三酸酯的能力。两种传统方法降低了体重增加和血浆胆固醇水平。相反，商业开菲尔没有有益效果。另外，四种传统酮中的一种降低了肝脏甘油三酸酯，这对应于脂肪酸合酶表达的降低，该脂肪酸合酶是一种参与肝脏脂肪形成的基因。连同肠道微生物组调节的证据，这项研究表明，传统的开菲尔具有改善与肥胖相关的代谢功能障碍的潜力。值得注意的是，开菲尔微生物种群的差异可能会影响传统开菲尔对宿主代谢健康产生积极影响的能力。
强调
Kefir, a fermented milk beverage, has shown promise in alleviating obesity and associated metabolic dysfunction. However, microbial characteristics are variable among traditional kefirs, and commercial kefirs drastically differ from traditional kefir. This study investigated the ability of four traditional and one commercial kefir to control weight gain, plasma cholesterol, and liver triglycerides in a high fat diet-induced obesity mouse model. Two traditional kefirs decreased weight gain and plasma cholesterol levels. Conversely, commercial kefir had no beneficial effect. Additionally, one of the four traditional kefirs lowered liver triglycerides, which corresponded with decreases in the expression of fatty acid synthase, a gene involved in liver lipogenesis. Together with evidence of gut microbiome modulation, this study shows that traditional kefir has the potential for improving metabolic dysfunction associated with obesity. Notably, differences in kefir microbial populations may influence the ability of traditional kefir to positively impact host metabolic health.